- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00015106
Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7
CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo
Study Overview
Detailed Description
Considerable progress in preclinical research has provided a basis for hypothesis driven clinical trials in cocaine dependence. A greater mechanistic understanding of both cocaine and many clinically approved medications has led to the identification of many promising medications for the treatment of cocaine dependence.
For this reason NIDA has developed a CREST (Clinical Rapid Evaluation Screening Trial) protocol to provide a needed incremental medication screening step between preclinical research and full blown expensive Phase III pivotal trials. While patients receive manual based psychotherapy, three medications are screened compared to unmatched placebo in an eight-week, 60-subject, four cell design trial. Other important features of the CREST protocol include collecting baseline measurements over a two week period and analyzing primary outcome measures (quantitative urine toxicology and clinical global improvement scales) in terms of a composite score of overall individual patient improvement.
The three medications being evaluated in this trial include reserpine, gabapentin and lamotrigine. Reserpine is being screened because of its well-known preclinical ability to functionally antagonize cocaine (by depleting neurochemicals elevated by cocaine). Gabapentin and lamotrigine are hypothesized to interfere with glutamatergic cocaine sensitization/kindling mechanisms relevant to addiction.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Cincinnati MDRU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females, 18 to 59 years of age.
- DSM-IV diagnosis of cocaine dependence as determine by a semi-structured clinical interview.
- Subjects must have at least two cocaine-positive urines (BE level >300 ng/ml) during the two week screening phase of the study.
- Subjects must have a self reported use of at least $100 worth of cocaine within the past 30 days.
- Ability to provide written informed consent and to comply with all study procedures.
- Women of child-bearing capacity must be using one of the following acceptable methods of birth-control: a. oral contraceptives, b. barrier (diaphragm or condom) with spermicide, c. intrauterine progesterone contraceptive system, d. levonorgestrel implant, e. medroxyprogesterone acetate contraceptive injection
Exclusion Criteria:
- Current dependence on any psychoactive substance other than cocaine, alcohol, or nicotine, physiological dependence on alcohol requiring medical detoxification.
- Subjects requiring treatment for neurological or psychiatric disorders.
- Subjects with any potentially life threatening or progressive medical illness other than addiction.
- Subjects with a history of hypertension currently requiring treatment.
- Subjects who have received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment or who have been on any experimental medication within the past 60 days.
- Females who are pregnant or lactating or having had three or more days of amenorrhea beyond the time of expected menses at the time of the first dose of study medication.
- Subjects who have clinically significant abnormal laboratory values as determined by the principal investigator.
- Subjects who have any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication.
- Chronic therapy with any medication which could interact adversely with one of the medications under study.
- Therapy with any of the opiate-substitutes (methadone, LAAM, buprenorphine) within 60 days of enrollment in this study.
- Subjects with a seizure disorder or with a history of a seizure disorder other than childhood febrile seizures or alcohol withdrawal seizures.
- Subjects with a history of major depression.
- Patients with a history of rashes or other sensitivity reactions to reserpine, lamotrigine, or gabapentin.
- Participant plans to receive psychosocial treatment external to that designated in the protocol during study participation.
- Subjects with systolic blood pressure below 100 mm of Hg., or diastolic blood pressure below 60 mm of Hg., who are symptomatic as determined by the physician conducting the screening medical history and phy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Adverse events
|
Urine toxicology for cocaine
|
Clinical improvement
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eugene Somoza, M.D., Ph.D., Cincinnati MDRU
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Lamotrigine
Other Study ID Numbers
- NIDA-5-0012-7
- Y01-5-0012-7
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine-Related Disorders
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA); Columbia UniversityNot yet recruitingCocaine Use Disorder | Cocaine Dependence | Cocaine Use | Cocaine Use Disorder, Moderate | Cocaine Use Disorder, Severe
-
Tonix Pharmaceuticals, Inc.National Institute on Drug Abuse (NIDA); PremierNot yet recruitingCocaine Use | Cocaine Abuse | Cocaine Adverse Reaction | Cocaine Intoxication | Cocaine Toxicity
-
Temple UniversityNational Institute on Drug Abuse (NIDA); University of PennsylvaniaCompletedCocaine-Related Disorders | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
Baylor College of MedicineNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Cocaine Dependence | Cocaine Abuse | Cocaine AddictionUnited States
-
University of VirginiaRecruitingCocaine Use Disorder | Cocaine Dependence | Ultrasound | Cocaine AbuseUnited States
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingCocaine Dependence | Cocaine Use | Cocaine Abuse | NeurotropismItaly
-
University Hospital Center of MartiniqueUnknown
Clinical Trials on Lamotrigine
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
University of Maryland, BaltimoreCompleted
-
GlaxoSmithKlineCompletedEpilepsy, PartialUnited States, Korea, Republic of, Ukraine, Chile, Costa Rica, Russian Federation, Puerto Rico, Argentina
-
University of ChicagoCompletedDermatillomania | Pathologic Skin Picking | Neurotic Excoriation | Psychogenic ExcoriationUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedMental DisordersUnited States
-
University Hospitals Cleveland Medical CenterGlaxoSmithKlineCompletedBipolar Disorder | Depression, BipolarUnited States